N
VRTX icon

Natixis’s Vertex Pharmaceuticals VRTX Stock Holding History

Natixis’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.5M Sell
48,192
-12,026
-20% -$5.61M 0.08% 181
2025
Q4 		$27.3M Buy
60,218
+30,412
+102% +$13.1M 0.1% 160
2025
Q3 		$11.7M Sell
29,806
-1,155
-4% -$483K 0.05% 265
2025
Q2 		$13.8M Sell
30,961
-24,473
-44% -$11.3M 0.06% 195
2025
Q1 		$26.8M Buy
55,434
+32,572
+142% +$15.2M 0.15% 113
2024
Q4 		$9.21M Sell
22,862
-13,865
-38% -$6.43M 0.06% 250
2024
Q3 		$17.1M Sell
36,727
-7,605
-17% -$3.65M 0.1% 148
2024
Q2 		$20.8M Sell
44,332
-306
-0.7% -$133K 0.12% 139
2024
Q1 		$18.7M Sell
44,638
-7,268
-14% -$3.07M 0.1% 160
2023
Q4 		$21.1M Sell
51,906
-129,266
-71% -$47.8M 0.15% 134
2023
Q3 		$63M Buy
181,172
+89,685
+98% +$31.4M 0.48% 40
2023
Q2 		$32.2M Buy
91,487
+73,987
+423% +$24.9M 0.26% 81
2023
Q1 		$5.51M Sell
17,500
-60,978
-78% -$18.3M 0.05% 261
2022
Q4 		$22.7M Buy
78,478
+55,193
+237% +$16.8M 0.13% 151
2022
Q3 		$6.74M Sell
23,285
-9,232
-28% -$2.66M 0.03% 351
2022
Q2 		$9.16M Buy
32,517
+27,221
+514% +$7.29M 0.03% 314
2022
Q1 		$1.38M Sell
5,296
-15,127
-74% -$3.59M ﹤0.01% 822
2021
Q4 		$4.49M Sell
20,423
-166,652
-89% -$32.4M 0.02% 575
2021
Q3 		$33.9M Buy
+187,075
New +$36.5M 0.12% 159
2021
Q2 		– Sell
-60,011
Closed -$12.9M – 1097
2021
Q1 		$12.9M Buy
60,011
+2,233
+4% +$490K 0.04% 332
2020
Q4 		$13.7M Buy
57,778
+37,522
+185% +$8.61M 0.05% 334
2020
Q3 		$5.51M Sell
20,256
-2,803
-12% -$773K 0.04% 256
2020
Q2 		$6.69M Buy
23,059
+13,516
+142% +$3.66M 0.05% 243
2020
Q1 		$2.27M Sell
9,543
-57,072
-86% -$13.1M 0.02% 368
2019
Q4 		$14.6M Sell
66,615
-119,454
-64% -$24.2M 0.09% 237
2019
Q3 		$31.5M Buy
186,069
+29,516
+19% +$5.22M 0.2% 110
2019
Q2 		$28.7M Buy
156,553
+107,947
+222% +$18.9M 0.22% 97
2019
Q1 		$8.87M Sell
48,606
-310,306
-86% -$57.3M 0.06% 293
2018
Q4 		$59.5M Buy
358,912
+196,919
+122% +$34.1M 0.49% 50
2018
Q3 		$31.2M Buy
+161,993
New +$28.8M 0.18% 131
2018
Q1 		– Sell
-487,993
Closed -$73.1M – 983
2017
Q4 		$73.1M Buy
487,993
+467,713
+2,306% +$69.3M 0.56% 45
2017
Q3 		$3.08M Buy
20,280
+14,547
+254% +$2.19M 0.03% 343
2017
Q2 		$739K Sell
5,733
-5,508
-49% -$663K 0.01% 456
2017
Q1 		$1.23M Sell
11,241
-322,171
-97% -$28.4M 0.02% 369
2016
Q4 		$24.6M Buy
+333,412
New +$27.1M 0.25% 101
2015
Q3 		– Sell
-7,442
Closed -$919K – 389
2015
Q2 		$919K Sell
7,442
-93,962
-93% -$11.8M 0.01% 215
2015
Q1 		$12M Sell
101,404
-27,649
-21% -$3.31M 0.16% 85
2014
Q4 		$15.3M Sell
129,053
-3,050
-2% -$344K 0.21% 73
2014
Q3 		$14.8M Buy
132,103
+114,935
+669% +$10.9M 0.23% 86
2014
Q2 		$1.63M Sell
17,168
-21,882
-56% -$1.53M 0.02% 255
2014
Q1 		$2.76M Buy
+39,050
New +$3.09M 0.04% 220
2013
Q3 		– Sell
-10,000
Closed -$799K – 560
2013
Q2 		$799K Buy
+10,000
New +$736K 0.01% 294

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Natixis's VRTX Position: Q1 2026 in Review

Natixis reduced its Vertex Pharmaceuticals (VRTX) stake by 20% in Q1 2026, selling an estimated $5.61M and leaving 48,192 shares worth $21.5M. The position accounts for 0.08% of the portfolio, ranked #181.

Natixis first reported a position in VRTX in Q2 2013 and has held it in 42 quarters since. The position peaked at $73.1M in Q4 2017. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Natixis held 48,192 shares of Vertex Pharmaceuticals worth $21.5M as of Q1 2026.
  • Natixis sold 12,026 Vertex Pharmaceuticals shares in Q1 2026, an estimated $5.61M.
  • Vertex Pharmaceuticals made up 0.08% of Natixis's portfolio in Q1 2026, its #181 holding.
  • Natixis first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
  • Natixis's Vertex Pharmaceuticals position peaked at $73.1M in Q4 2017.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.